We investigated the clinical profiles associated with serum uric acid (sUA) levels in a large cohort of patients hospitalized for worsening chronic heart failure with ejection fraction (EF) ≤&40%, with specific focus on gender, race, and renal function based interactions. In 3,955 of 4,133 patients (96%) with baseline sUA data, clinical characteristics and outcomes were compared across sUA quartiles. The primary end points were all-cause mortality and a composite of cardiovascular mortality or heart failure hospitalization. Interaction analyses were performed for gender, race, and baseline renal function. Median follow-up was 9.9 months. Mean sUA was 9.1 ;plusmn& 2.8 mg/dl and was higher in men than in women (9.3 ;plusmn& 2.7 vs 8.7 ;plusmn& 3.0 mg/dl, p <0.001) and in blacks than in whites (10.0 ;plusmn& 2.7 vs 9.0 ;plusmn& 2.8 mg/dl, p <0.001). Higher sUA was associated with lower systolic blood pressure and EF, higher natriuretic peptides, and more impaired renal function. After accounting for 24 baseline covariates, in patients with enrollment estimated glomerular filtration rate ≥30 ml/min/1.73 m;bsupesup, sUA was strongly associated with increased all-cause mortality (hazard ratio 1.44, 95% confidence interval 1.22 to 1.69, p <0.001) and the composite end point (hazard ratio 1.44, 95% confidence interval 1.26 to 1.64, p [removed]0.4). Adjusted interaction analyses for gender, race, and admission allopurinol use were not significant. In conclusion, sUA is commonly elevated in patients hospitalized for worsening chronic heart failure and reduced EF, especially in men and blacks. The prognostic use of sUA differs by baseline renal function, suggesting different biologic and pathophysiologic significance of sUA among those with and without significant renal dysfunction.

Vaduganathan, M., Greene, S., Ambrosy, A., Mentz, R., Subacius, H., Chioncel, O., et al. (2014). Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan Trial). THE AMERICAN JOURNAL OF CARDIOLOGY, 114(11), 1713-1721 [10.1016/j.amjcard.2014.09.008].

Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan Trial)

Senni M;
2014

Abstract

We investigated the clinical profiles associated with serum uric acid (sUA) levels in a large cohort of patients hospitalized for worsening chronic heart failure with ejection fraction (EF) ≤&40%, with specific focus on gender, race, and renal function based interactions. In 3,955 of 4,133 patients (96%) with baseline sUA data, clinical characteristics and outcomes were compared across sUA quartiles. The primary end points were all-cause mortality and a composite of cardiovascular mortality or heart failure hospitalization. Interaction analyses were performed for gender, race, and baseline renal function. Median follow-up was 9.9 months. Mean sUA was 9.1 ;plusmn& 2.8 mg/dl and was higher in men than in women (9.3 ;plusmn& 2.7 vs 8.7 ;plusmn& 3.0 mg/dl, p <0.001) and in blacks than in whites (10.0 ;plusmn& 2.7 vs 9.0 ;plusmn& 2.8 mg/dl, p <0.001). Higher sUA was associated with lower systolic blood pressure and EF, higher natriuretic peptides, and more impaired renal function. After accounting for 24 baseline covariates, in patients with enrollment estimated glomerular filtration rate ≥30 ml/min/1.73 m;bsupesup, sUA was strongly associated with increased all-cause mortality (hazard ratio 1.44, 95% confidence interval 1.22 to 1.69, p <0.001) and the composite end point (hazard ratio 1.44, 95% confidence interval 1.26 to 1.64, p [removed]0.4). Adjusted interaction analyses for gender, race, and admission allopurinol use were not significant. In conclusion, sUA is commonly elevated in patients hospitalized for worsening chronic heart failure and reduced EF, especially in men and blacks. The prognostic use of sUA differs by baseline renal function, suggesting different biologic and pathophysiologic significance of sUA among those with and without significant renal dysfunction.
Articolo in rivista - Articolo scientifico
African Americans; Age Factors; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Pressure; European Continental Ancestry Group; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptides; Prognosis; Proportional Hazards Models; Renal Insufficiency; Risk Factors; Sex Factors; Stroke Volume; Systole; Treatment Outcome; Uric Acid; Ventricular Dysfunction, Left;
English
1713
1721
9
Vaduganathan, M., Greene, S., Ambrosy, A., Mentz, R., Subacius, H., Chioncel, O., et al. (2014). Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan Trial). THE AMERICAN JOURNAL OF CARDIOLOGY, 114(11), 1713-1721 [10.1016/j.amjcard.2014.09.008].
Vaduganathan, M; Greene, S; Ambrosy, A; Mentz, R; Subacius, H; Chioncel, O; Maggioni, A; Swedberg, K; Zannad, F; Konstam, M; Senni, M; Givertz, M; Butler, J; Gheorghiade, M
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/372091
Citazioni
  • Scopus 41
  • ???jsp.display-item.citation.isi??? 41
Social impact